Pharmacology and toxicology of the compounds are evaluated in animal models to determine the pharmacokinetic properties of the drug of interest, as well as an effort to optimize potential therapeutic index. Suitable formulations, to allow systemic administration of the agent, as well as the optimal route and schedule of administration, are developed. DTP, through a coordinated contract supported program, can synthesize compounds of interest in small quantities required for initial study or GMP-grade bulk material in support of clinical trials. Compounds originating outside the DTP screening program that have demonstrated in vitro or in vivo activity may be submitted for consideration of development at any stage in the Decision Network process. The ultimate aim of the program is both the discovery and preparation of new agents for clinical evaluation.
Complete confidentiality is assured through the use of discreet agreements.
The intellectual property of the contributor or collaborator is absolutely protected. DTP welcomes interactions with individual investigators, academic institutions as well as corporate partners.